Ryan Hoggan, MD
Rheumatology · Layton, UTNPI 1881013951
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.9% of the total across 749 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 23.8% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,897, 3.3 times the $568 reported in 2019.
Across 749 payments — averaging $13.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$2K
- Pfizer$1K
- AbbVie$1K
- Johnson & Johnson$1K
- GSK$617
- UCB, Inc.$599
- plus $3K from 24 others
Across 3 payments — averaging $8409.33 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$25K
What the payments were for
- Food & beverage$10,05697%
- Education$3173%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 171 | $2,470 |
| Pfizer | 166 | $1,276 |
| AbbVie | 85 | $1,199 |
| Johnson & Johnson | 56 | $1,021 |
| GSK | 31 | $617 |
| UCB, Inc. | 56 | $599 |
| Novartis | 28 | $554 |
| Lilly USA, LLC | 23 | $414 |
| AstraZeneca | 24 | $399 |
| Organon | 28 | $374 |
| E.r. Squibb & Sons, L.L.C. | 12 | $200 |
| Genentech USA, Inc. | 9 | $161 |
| Fresenius Kabi USA, LLC | 8 | $158 |
| Boehringer Ingelheim | 7 | $146 |
| ANI Pharmaceuticals, Inc. | 6 | $134 |
| Sandoz | 5 | $111 |
| Sobi, Inc | 5 | $81 |
| Regeneron Healthcare Solutions, Inc. | 4 | $69 |
| Sanofi | 4 | $65 |
| Actelion Pharmaceuticals US, Inc. | 5 | $57 |
| Merck | 3 | $46 |
| Bristol Myers Squibb | 3 | $45 |
| Mallinckrodt Hospital Products Inc. | 2 | $38 |
| Ferring Pharmaceuticals Inc. | 2 | $31 |
| Mylan Institutional Inc. | 1 | $21 |
| Aurinia Pharma U.S., Inc. | 1 | $20 |
| Teva Pharmaceuticals USA, Inc. | 1 | $20 |
| Shield Therapeutics Inc | 1 | $16 |
| Ultragenyx Pharmaceutical Inc. | 1 | $15 |
| Antares Pharma, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BENLYSTA$125
How this compares
$10,374 in reported general payments places this provider in the 80th percentile of 52 rheumatology providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enbrel SureclickEtanercept | 72 | $558,376 |
| Humira(Cf) PenAdalimumab | 22 | $154,840 |
| Teriparatide | 22 | $49,171 |
| Hydroxychloroquine Sulfate | 290 | $14,126 |
| MethotrexateMethotrexate Sodium | 205 | $5,825 |
| Cevimeline Hcl | 11 | $3,465 |
| Sulfasalazine DrSulfasalazine | 70 | $3,370 |
| Febuxostat | 23 | $2,692 |
| Sulfasalazine | 66 | $1,928 |
| Leflunomide | 34 | $1,767 |
| Celecoxib | 65 | $1,712 |
| Azathioprine | 47 | $1,156 |
| Folic Acid | 65 | $1,069 |
| Methylprednisolone | 35 | $953 |
| Diclofenac Sodium | 37 | $919 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in Layton
- Michael YoungLayton$9K
- Gregory AustadLayton$7K
- Catherine BakewellSalt Lake City$1M
- Jessica WalshSlc$162K
- Shruti SanghviVineyard$63K
- Curry KoeningSalt Lake City$59K
- Carmen GotaSt. George$56K
- Seung Yoon LeeMurray$22K
- Matthew CallSpringville$17K
- Wenshu YuProvo$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.